Quarterly ResultAug 13, 2026, 04:23 PM
Equillium H1 Net Loss $(10.0)M; Cash $57.2M After $35M Raise
AI Summary
Equillium, Inc. reported a net loss of $(10.0) million for the six months ended June 30, 2026, an improvement from $(14.4) million in the prior year. The company significantly strengthened its financial position with cash and cash equivalents reaching $57.2 million, primarily due to a $35.0 million private placement in March 2026. Management expects current cash to fund operations into 2029, supporting the advancement of its clinical programs, including a planned Phase 1 study for EQ504 in Q4 2026.
Key Highlights
- Net loss for H1 2026 improved to $(10.0) million from $(14.4) million in H1 2025.
- Cash and cash equivalents increased to $57.2 million as of June 30, 2026, from $30.3 million at year-end 2025.
- Completed a $35.0 million private placement in March 2026, issuing common stock and pre-funded warrants.
- Operating expenses decreased to $10.8 million in H1 2026 from $15.1 million in H1 2025.
- Net cash used in operating activities improved to $(8.4) million in H1 2026 from $(11.2) million in H1 2025.
- Stockholders approved increasing authorized common stock from 200 million to 400 million shares.
- Plans to initiate a Phase 1 study for EQ504 in Q4 2026 for ulcerative colitis.
Price Impact
More from EQ